News | September 29, 2010

Data Released on Drug-Eluting Balloons for PAD

September 29, 2010 – Results from a trial studying the effects of a drug-eluting balloon (DEB) on peripheral artery disease (PAD) were released at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium.

The IN.PACT SFA I trial is investigating the safety and efficacy of Medtronic's Admiral paclitaxel-eluting percutaneous transluminal angioplasty (PTA) balloon catheter in the superficial femoral artery (SFA) compared to treatment with a standard PTA balloon.

“Based on a growing body of clinical data and while results of randomized trials are awaited, IN.PACT drug-eluting balloons show great promise for the treatment of both coronary and peripheral artery disease,” said Bruno Scheller, M.D., professor of internal medicine and cardiology at the University of Saarland in Homburg/Saar, Germany. “The best potential applications appear to be in atherosclerotic leg vessels and for previously stented coronary arteries that have restenosed. Drug-eluting balloons may very well become the fourth therapeutic platform for cardiovascular interventions, joining traditional balloon angioplasty, bare-metal stents and drug-eluting stents.”

The drug-eluting balloons feature a hydrophilic coating called FreePac that frees and separates paclitaxel molecules, facilitating their absorption into the vessel wall to mitigate re-narrowing of the artery over time. The program consists of studies on the treatment of de-novo coronary lesions and coronary in-stent restenosis, as well as below-the-knee (BTK) and superficial femoral artery (SFA) disease.

The IN.PACT Admiral DEB and the IN.PACT Falcon DEB received the CE mark in 2009 and are available in more than 100 countries around the world. They are not available in Canada, Japan and the United States.

For more information: www.medtronic.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init